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ABSTRACT
Introduction: Poor compliance and incorrect
handling of inhaler devices is common among
patients with asthma using traditional dry
powder inhalers, and patient preference and
perception of ease of handling are important.
The aim of this study was to determine the
proportion of patients preferring the recently
introduced Novopulmon Novolizer device
(Meda, Sweden) compared with their previous
inhaler device.
Methods: An observational study was
conducted among 258 asthma patients in
Sweden. Patients aged C6 years, receiving
maintenance treatment with inhaled
corticosteroids, and requiring a switch to
another inhaler were included. Patients
completed a questionnaire regarding the
preference, appearance, handling, instructions
for use, dose control, and global perception of
the inhaler upon switching the device and
again after 2 months’ use of the new device.
Results: Patients were aged from 6 to 85 years.
Almost all patients (98%) were switched to the
Novolizer inhaler. The majority of patients
preferred Novolizer versus their previous
inhaler: 92.4% [95% confidence interval (CI)
86.0–96.5%] in the 6–12 years age group, 90.9%
(95% CI 70.8–98.9%) in the 13–17 years group,
and 83.3% (95% CI 74.4–90.2%) among those
aged C18 years. The results from 10 questions
related to the inhalation process and device
handling demonstrated that Novopulmon
Novolizer was evaluated by patients as superior
compared with Turbuhaler (AstraZeneca),
Diskus (GlaxoSmithKline) and Easyhaler
(Orion); P\0.022 for all comparisons.
Conclusion: Novopulmon Novolizer was
determined by patients to be the preferred
device compared with previously used devices,
and was the patients’ preference for continued
use. In particular, the Novolizer’s audible, visual
and sensory feedback mechanisms (that identify
whether the correct dose is loaded and
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administered) and its general ease of use were
highly appreciated by asthma patients.
Together this makes the Novopulmon
Novolizer an ideal first choice inhaler for
treatment of asthma, and also for patients who
need to switch inhaler.
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INTRODUCTION
Asthma is a common, chronic disease affecting
around 300 million individuals worldwide [1].
Treatment of asthma with inhaled
corticosteroids (ICSs) is recommended by the
Global Initiative for Asthma (GINA) [1]. It is
very important that the ICS is correctly taken
[2]; however, poor compliance and incorrect
handling of inhalers are frequent among people
with asthma [3]. Patient preferences and
opinions of the inhaler properties play a
pivotal role for treatment outcomes. How
patients perceive the handling of the device is
often neglected [4]. Faulty technique can
sabotage even the best of treatment plans for
asthma [5].
Most patients cannot use the pressurized
metered dose inhaler correctly [6, 7], and while
dry powder inhalers (DPIs) are easier to use,
patients also make mistakes when using these
[8]. The Novolizer (Meda, Sweden) inhaler
device was specifically designed to overcome
many of the disadvantages associated with other
DPIs. Compared to other DPIs, the Novolizer has
a low-medium intrinsic resistance, and still
patients need only to generate an inspiratory
flow rate of 35 L/min for optimal drug delivery
[9]. The dynamic resistance of the Novolizer is
5.5-times lower than that of the Turbuhaler
(AstraZeneca) and patients achieve significantly
higher peak inspiratory flow rates and better
inhalation performance with the Novolizer [10,
11]. The Novopulmon Novolizer deposits
significantly more budesonide into the lungs
than the Turbuhaler, more reliably, and with less
variability of lung deposition [12–14]. In
addition, the Novolizer is simple to use and
simple to refill, rendering it forgiving of poor
patient technique [15]. The optical, acoustic, and
sensory feedback systems guide patients through
a successful inhalation maneuver and provide
confidence that the drug has reached the lungs
[15–17].
The present study was performed in patients
who were prescribed a switch of DPI in standard
clinical practice by their physician. The main
objective of this study was to determine the
proportion of patients preferring the new
inhaler upon switching device as well as after
using new inhaler device. Secondary objectives
were to determine the reasons for switching and
to survey the patients’ positive/negative
opinions of different properties and functions
of their ICS inhaler.
METHODS
Patients
Male and female asthma patients of C6 years of
age were included. To be eligible for the study,
patients had to be receiving maintenance
treatment with an ICS DPI (Step 2 according
to GINA guidelines) [1] and a switch from the
existing DPI to any other type of DPI was
considered necessary.
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Design
This was a multicenter, prospective,
observational study conducted at 50 primary
care and hospital care centers in Sweden. The
study was performed according to European
regulations for non-interventional,
observational studies [18, 19] and approved by
the Ethics Committee of Lund, Sweden. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study. For
patients below 18 years of age, both the patient
and the patient’s guardian received verbal and
written information about the study and signed
informed consent. The informed consent for
patients 6–12 years of age was in a lay language
intended for this group. The study period was
carried out between January 2011 and
September 2012. The new inhaler was
prescribed by the investigator according to the
summary of product characteristics (SPC).
Patients with any contraindication according
to the SPC to the new DPI treatment were
excluded. For the switch, no study-specific
procedure for informing and/or presenting the
new inhaler was given. The intention was to
keep the real-life procedures information/
demonstration intact in order to minimize
influence on the results.
The study design incorporated a first visit
together with a patient questionnaire
concerning the previously used inhaler and a
follow-up questionnaire with reference to
different aspects of the new and old inhalers
(function and properties) completed 2 months
later.
Data Collection
The questionnaire was presented and collected
by either a nurse or the investigator, in-line
with routines at the specific clinic. A few
questions were specific to the previous inhaler
and the new inhaler had one unique question,
which was preference for future use. Patients
were asked to answer questions regarding
appearance, handling, instruction for use, dose
control, and global perception of the inhaler at
study entry and at the second visit after
6–10 weeks. At the follow-up visit, a question
regarding patient’s preference of inhaler was
asked. The novel questionnaire was based on
pre-study discussions with experienced
pediatrician/allergologist regarding the
clinically relevant, key questions (Table S1 in
the electronic supplementary material).
Primary and Secondary Efficacy Endpoints
The primary efficacy endpoint was the
proportion of patients preferring the new
inhaler. Secondary efficacy endpoints were
patient’s opinion of properties and functions
of the inhaler both before and after the switch,
past and present type of inhaler and the main
reason for the patient’s switch of inhaler.
Statistics
It was estimated that a sample size of 323
evaluable patients was required to obtain a
two-sided 95% confidence interval (CI) with the
width ±5% units for an expected proportion of
patients who prefer the new inhaler of 70%. The
results were to be presented by age group
(6–12 years, 13–17 years, and 18? years). The
primary efficacy endpoint, proportion of patients
preferring the new inhaler was presented by a
Pulm Ther (2015) 1:65–75 67
point estimate and a 95% CI. Since the normal
approximation fails when the proportion is close
to 1, an exact Clopper–Pearson CI was calculated.
The secondary endpoints were assessed on a
5-point ordinal scale (e.g., from very difficult to
very easy) in 10 questions. Each of these
endpoints was tested with a proportional odds
model for repeated measure within patient. The
factors age group, sex, status (old or new inhaler),
and type of old inhaler were tested for inclusion
in the model and the final model included
significant factors only. The odds ratio (OR)
with corresponding 95% CI for new versus old
inhaler and P value are presented. In this study,
an OR [1 implies that the new inhaler has a
more favorable result (e.g., more easy to use).
Answers to further four questions regarding
functions of the inhaler and training on
inhalers were presented as summary statistics.
All statistical analyses were performed using SAS
(Version 9.3, SAS Institute Inc., Cary, NC, USA).
Safety
Suspected adverse drug reactions (ADRs) were
assessed and documented in the case report
form (CRF). The physician was required to
document whether a reasonable causal
relationship with the drug (yes/no) could be
assigned for each adverse reaction reported.
RESULTS
Patient Disposition
The planned sample size of 323 patients was not
reached at study termination after 19 months.
After termination, a total of 280 subjects were
recruited and of these 17 did not return for the
final visit. Full patient disposition is provided in
Table 1.
Since most patients switched from an ICS
DPI to the Novopulmon Novolizer inhaler
(98%), a modified intent-to-treat (ITT) data set
of these patients was selected for the efficacy
evaluation. Very few patients switched to
Diskus (GlaxoSmithKline); 3 patients or
Easyhaler (Orion); 2 patients and thus these
were not included in the efficacy analysis
(Table 1). To allow for comparison between
the major brands, further 11 patients that had
not used Diskus, Easyhaler, or Turbuhaler as the




Patients enrolled and allocated to treatment, n (%) 3 (1%) 2 (1%) 275 (98%) 280
Patients excluded, n







Number of subjects in safety analysis, n (%) 3 2 253 (92%) 258 (92%)
Number of subjects in the modiﬁed ITT efﬁcacy analysisa, n (%) 0 0 242 (88%) 242 (86%)
ITT intent-to-treat
a Excluded from modiﬁed ITT (n = 11) patients who had not received either Turbuhaler, Diskus, or Easyhaler as the old
inhaler treatment
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old ICS DPI were also excluded from the
modified ITT efficacy analysis (n = 242).
Patient Demographics
The age and sex distribution of patients
included in the analysis is shown in Tables 2
and 3 for the modified ITT efficacy analysis data
set. The age of the participating patients ranged
between 6 and 85 years.
Previous Inhaler Use
Turbuhaler, Diskus, and Easyhaler were the
most commonly previously used DPIs for all
age groups (Table 3). Nine patients had used
other inhalators (including spray devices), of
which four patients had previously used the DPI
product Asmanex (mometasone; Merck Sharp
& Dohme). The mean duration of use of
previous inhaler was between 0.89 and
5.11 years (mean 4.50, median 2.11).
Table 2 Patient demographics by age group, and sex: analysis data set
6–12 years 13–17 years 181 years Total
n 124 24 110 258
Age (years)
Mean (SD) 8.7 (2.0) 14.2 (1.1) 53.9 (15.2) 28.5 (24.2)
Q1, Q3 7.0, 10.0 13.0, 14.5 41.0, 67.0 9.0, 49.0
Median (min, max) 8.0 (6, 12) 14.0 (13, 17) 55.5 (19, 85) 13.0 (6, 85)
Sex
Male, n (%) 86 (69%) 13 (54%) 37 (34%) 136 (53%)
Female, n (%) 38 (31%) 11 (46%) 73 (66%) 122 (47%)
Table 3 Patient demographics by age group, sex, and inhaler use: modiﬁed intent-to-treat efﬁcacy analysis data set
Age group Old inhaler Novopulmon Novolizer
(new inhaler)Diskus Easyhaler Turbuhaler
6–12 years 30 (25%) 12 (10%) 76 (64%) 118 (100%)
Male 24 (80%) 9 (75%) 51 (67%) 84 (71%)
Female 6 (20%) 3 (25%) 25 (33%) 34 (29%)
13–17 years 6 (26%) 1 (4%) 16 (70%) 23 (100%)
Male 5 (83%) 0 (0%) 7 (44%) 12 (52%)
Female 1 (17%) 1 (100%) 9 (56%) 11 (48%)
18? years 11 (11%) 11 (11%) 79 (78%) 101 (100%)
Male 5 (46%) 5 (46%) 25 (32%) 35 (35%)
Female 6 (54%) 6 (54%) 54 (68%) 66 (65%)
Data are presented as n (%)
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Efficacy
Primary Endpoint
Almost all patients (98%) were switched to the
Novopulmon Novolizer as their new inhaler. For
the primary outcome, the majority of patients
selected the Novolizer as their choice of inhaler
to continue using in the future: 92.4% (95% CI
86.0–96.5%) of 6–12-year-old, 90.9% (95% CI
70.8–98.9%) of 13–17-year-old, and 83.3% (95%
CI 74.4–90.2%) of those aged 18 years and above.
Secondary Endpoints
Reason for Switching The main reasons for
switching DPI (whether it is Diskus, Easyhaler,
or Turbuhaler) were ‘Insufficient asthma
control’ and ‘Patient’s wish’ across all age
groups, while handling problems were also
frequently reported among those aged
6–12 years (Fig. 1). Insufficient asthma control
appeared particularly pertinent to patients’
desire to switch from the Easyhaler for all the
age groups assessed. The main reasons given
were not based on pre-defined definitions.
Inhaler Properties For all properties and
functions, more outcomes are favorable for the
Novopulmon Novolizer as compared to the
previously used inhaler (Fig. 2). Compared
with previously used inhalers, patients
switched to the Novopulmon Novolizer found
it easier to load, easier to inhale through, and
easier to tell if they had inhaled the medicine.
The patient’s overall opinion of the
Novopulmon Novolizer was also higher than
that of previously used devices (OR 7.74; 95% CI
5.27–11.4; P\0.0001). Compared with
previously used inhalers, patients switched to
Novopulmon Novolizer also found it easier to
use, easy to learn how to use and easy to know
how much drug was left in the inhaler. Patients
preferred the shape and size of the Novopulmon
Novolizer compared with their previously used
DPI and found it easier to carry with them
(Fig. 2). Overall, the Novopulmon Novolizer
was evaluated by patients as superior
compared with the previously used devices
(P\0.022 for all comparisons).
Answers to four questions concerned with
inhaler function and training on inhaler usage
are presented as summary statistics. For all age
groups, the most common ways in which
patients learned to use their inhaler device
(both old and new inhalers) was by oral
presentation, physician demonstration, and
third, nurse demonstration, with no
Fig. 1 Main reason for the patient’s switch of inhaler, by
type of old inhaler. a Age group 6–12 years; b age group
13–17 years; c age group 18? years
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appreciable difference in teaching approach
between the old and new device.
Demonstration of inhaler technique by the
patient occurred more frequently in the
younger age groups (approximately 80% of
patients) than for those aged 18 years and
above (approximately 50% of patients).
Around one-fifth to one-half of all patients had
received repeat information on how to use the old
inhaler device prior to switching (18% to 53%
across the age groups). Repeat demonstration of
inhaler technique by the patient using the old
device occurred more frequently among younger
patients (58% of 6–12 year olds and 56% of
13–17 year olds) than among adults (18%).
Patients judged that the most valuable
functions for knowing if the medicine was
taken were ‘hearing a sound,’ ‘change of
color,’ and ‘taste sensation.’
Safety
Three ADRs were reported in the study by
patients that switched to the new inhaler
Novopulmon Novolizer, which led to
treatment discontinuation; these included
teeth discoloration, erythema, and cough.
DISCUSSION
This study was performed in patients who were
prescribed a switch of DPI in standard clinical
practice by their physician, and was designed to
collect data on how patients evaluate a new
inhaler when switching from a previously used
inhaler. The key finding of this study is that the
vast majority of patients across the age groups
preferred to continue to use the new
Novopulmon Novolizer at study end. A further
finding of the study is that patients rated the
new Novopulmon Novolizer inhaler as
significantly superior versus the previous
inhaler used across a number of questions
concerned with properties and function of the
inhaler device (P\0.022 for all comparisons).
Compared with previously used inhalers,
patients switched to Novopulmon Novolizer
Is it easy or difficult to know if you
have inhaled your medicine?
Is it easy or difficult to know if you have 
loaded the right dose in your inhaler?
What is your overall opinion
about your inhaler? 
How easy do you find it is to
inhale with your inhaler?
How easy do you find it is
to use your inhaler?
How easy did you find it to learn
how to use your inhaler?
Do you think it is easy or difficult to know
how much drug is left in the inhaler?
How do you like the shape
of your inhaler?
How do you like the size
of your inhaler?
How easy do you find it is to




































Odds ratio for a more favorable outcome with the new inhaler
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Fig. 2 Likelihood of a more favorable outcome with the
new inhaler Novopulmon Novolizer compared with the
previously used inhaler for answers given by patients to ten
questions included in the questionnaire. The odds ratio
(OR) with corresponding 95% conﬁdence interval (CI) for
new versus old inhaler and P value are presented; an OR[1
implies that the new inhaler has a more favorable result
(e.g., more easy to use)
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found it easier to use, easy to load and inhale
through, and easy to know how much drug was
left in the inhaler. The device attributes
associated with patient preference for the
Novopulmon Novolizer shown here, are
consistent with recent findings by Price et al.
[20]. They found higher device satisfaction with
attributes including consistency in the amount
of drug delivery to the lungs, ease of use, and
feedback about the number of remaining doses.
Higher patient satisfaction with their asthma
drug delivery device was further shown to be a
significant predictor of higher medication
adherence and more favorable clinical
outcomes [20]. The patient’s preferences and
opinions of the properties of the inhaler plays a
pivotal role for treatment outcome, and the
patient’s perception of the handling of the
device is often neglected [4]. However, the
level of patient satisfaction with their inhaler
device is demonstrated to have a positive
influence on compliance and achievement of
treatment goals for asthma [20, 21]. Regrettably,
poor compliance and incorrect handling of
inhalers is common among people with
asthma [3, 22]. When technique is markedly
flawed, suboptimal outcomes typically result,
such as poor asthma control and increased
frequency of emergency department visits [1,
5, 6, 22–24]. The Novolizer is a technically
advanced DPI, which comprises a number of
features that should improve compliance,
safety, and efficacy. We have demonstrated
that the Novolizer is associated with high
patient preference, and it is suitable for
patients with asthma regardless of severity [25].
The ease of handling of the Novopulmon
Novolizer device with audible, visual, and
sensory feedback mechanisms are attributes
that contribute to the higher degree of patient
preference. These attributes combined with
medium airflow resistance makes the device
suitable for use especially in very young patients
able to use a DPI and for elderly patients who
may not be capable of generating sufficient
inhalation flow [16]. The Novolizer device has
shown lower variability in lung deposition
in vivo compared with the Turbuhaler device
[14]. Handling problems with the previously
used device were more frequently reported
among the younger age group (aged
6–12 years) as the reason for switching. Future
studies should explore the clinicians’ and
patient/guardians’ views on switching from
metered dose inhalers to DPIs in young
patients suitable for DPIs.
Strength of this study is that it is a real-life
clinical situation comparing previous inhaler
use with the Novopulmon Novolizer.
Randomized controlled trials usually exclude
patients with suboptimal inhaler technique [3,
22]. Other published studies, systematic
reviews, and guidelines have shown that
patients do not get the full value of their
inhaled medications because they use their
inhaler incorrectly. Errors are made in
inhalation technique and handling of the
inhaler devices [6, 8, 22, 26].
The findings of our study are in-line with
those of Perpin˜a´ Tordera et al. [27] who
investigated patient satisfaction and preference
for three different inhalers, Novolizer,
Turbuhaler, and Accuhaler after one week of
use. In the younger age group below 16 years,
the preferred inhaler was Novolizer (60%) while
Turbuhaler and Accuhaler were only preferred
by 20% of patients in each case (P = 0.04).
However, for the overall group no significant
difference for preference was seen between the
inhalers. In an earlier 4-week observational
study, Novolizer was rated as better than
previously used inhalers by 83% of patients
[28]. In a further 4-week observational study, an
improvement in compliance due to the control
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mechanisms of the Novopulmon Novolizer was
observed in 80% of the 3057 patients [29].
At the time when the study started
Novopulmon Novolizer had recently been
launched in Sweden and was perceived
among physicians as an inhaler with several
unique features. This may have contributed to
the high percentile switch to Novopulmon
Novolizer (98%). Another possible reason for
the high preference for Novopulmon Novolizer
could have been that the patients were
discontent with their current inhaler at the
time of switch. A high proportion of patients,
50–80%, were able to demonstrate their
inhalation technique with the previously used
inhaler at the patient consultation and had
used the old device for 0.89 to 5.11 years, but
still a majority preferred the new inhaler at
study end. The new inhaler Novopulmon
Novolizer was well tolerated with few ADRs
(n = 3) reported that led to treatment
discontinuation.
A limitation of the study is that it is not a
randomized cross-over study where all inhalers
are compared. Another possible limitation may
be that patient expectation plays a role in
perceived benefit. Clerisme-Beaty and
co-workers [30] suggest that the methods by
which treatment options are introduced to
patients not only affect adherence to therapy
and clinical outcomes, but also affect
self-reported outcomes. The interaction
between outcome expectancy and inhaler/drug
efficacy is complex and includes that failure to
notice the expected benefit may negatively
affect adherence [30]. The level of satisfaction
and preference for the Novopulmon Novolizer
could have been influenced by a positive
response to the novelty of the Novopulmon
Novolizer. Nonetheless, the outcome was
favorable for all parameters and should
therefore also reflect a real-life advantage.
CONCLUSIONS
The main finding of this observational real-life
study is that the vast majority of asthma
patients (83.3% to 92.4%) across all age groups
preferred to use the new Novopulmon
Novolizer inhaler compared with their
previous inhaler devices (Turbuhaler, Diskus,
and Easyhaler) and to continue to use the
Novolizer beyond the study end. Furthermore,
patients rated the Novolizer inhaler as
significantly superior versus the previously
used inhaler across all questions concerned
with properties and function of the inhaler
device (P\0.022 for all comparisons). In
particular, the Novolizer’s audible, visual and
sensory feedback mechanisms (that identify
whether the correct dose is loaded and
administered) and its general ease of use were
rated highly by asthma patients. These results
are in-line with earlier study results in asthma
and chronic obstructive pulmonary disease
patients where the unique technical features of
the Novolizer demonstrated significant
advantages compared with other inhalers.
Combined, this makes the Novopulmon
Novolizer an ideal first choice inhaler for the
treatment of asthma, also in patients who need
to switch inhaler.
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